Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405904 | 0.82 | HSD11B1 (0.59) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL6359707 | 0.79 | PKM (0.51) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL10960723 | 0.78 | ALDH1A1 (0.71) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL7823769 | 0.77 | POLB (0.49) | SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL15452739 | 0.77 | HTT (0.64) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL4825713 | 0.75 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL27538679 | 0.73 | SMN1; SMN2 (1.00) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL10678819 | 0.73 | ALDH1A1 (0.55) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL9447466 | 0.73 | ALDH1A1 (0.62) | PKMSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL6361554 | 0.73 | HSD11B1 (0.49) | PKMSMN1; SMN2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | PKM 360/4885SMN1; SMN2 972/4885ALDH1A1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.